공시 • Jun 04
ClinActiv Holdings Inc. completed the acquisition of Crescita Therapeutics Inc. (TSX:CTX). ClinActiv Holdings Inc. entered into a definitive arrangement agreement to acquire Crescita Therapeutics Inc. (TSX:CTX) for CAD 15.4 million on March 14, 2026. A cash consideration of CAD 15.4 million valued at CAD 0.8 per share will be paid by the buyer, subject to upward or downward adjustment based on the Company’s net working capital balance at the closing of the Arrangement, subject to a minimum purchase price of CAD 0.75 per Share. As part of consideration, CAD 15.4 million is paid towards common equity of Crescita Therapeutics Inc. The Arrangement Agreement includes a termination fee of CAD 2.0 million, and reverse termination fee of CAD 2.1 million ($1.5 million).
The deal is subject to approval by shareholders of Crescita Therapeutics Inc. and receipt of court approval, and other customary conditions, Dissent Rights and minimum closing net cash. The transaction has been unanimously approved by the board of directors of Crescita Therapeutics and recommended that shareholders vote for the arrangement. The Arrangement is conditional on the Company having minimum cash and net working capital balances at closing. The deal is expected to close in the second quarter of 2026. As of April 22, 2026, Crescita Therapeutics Inc. filed and mailed shareholder meeting materials in connection with a special meeting to be held on May 14, 2026, seeking shareholder approval of the proposed arrangement with ClinActiv Holdings Inc. On May 14, 2026, the shareholders of Crescita Therapeutics approved the transaction. On May 20, 2026, Crescita Therapeutics Inc. announced that it has obtained a final court order from the Ontario Superior Court of Justice (Commercial List) approving the transaction. Upon closing of the arrangement, it is expected that the Crescita Therapeutics shares will be delisted from the Toronto Stock Exchange and that it will apply to the applicable Canadian securities regulators to cease to be a reporting issuer under applicable Canadian securities laws. As of June 1, 2026, the final consideration payable to the shareholders of Crescita is $0.8 per share and the transaction is expected to close on June 3, 2026.
Bloom Burton Securities Inc. acted as financial advisor and fairness opinion provider for Crescita Therapeutics Inc. Chris Sunstrum of Goodmans LLP acted as legal advisor for Crescita Therapeutics Inc. BCF LLP acted as legal advisor for Crescita Therapeutics Inc. Aaron Sonshine of Bennett Jones LLP is acting as legal advisor to ClinActiv Holdings. TSX Trust Company acted as depositary bank to Crescita Therapeutics.
ClinActiv Holdings Inc. completed the acquisition of Crescita Therapeutics Inc. (TSX:CTX) on June 3, 2026. 공시 • May 17
Crescita Therapeutics Expects its Shares to Be Delisted from the Toronto Stock Exchange Upon Closing of the Arrangement Crescita Therapeutics Inc. (the “Company”) announced that at its special meeting (the “Meeting”) of shareholders (the “Shareholders”) held in person on May 14, 2026, Shareholders voted overwhelmingly in favour of the special resolution (the “Arrangement Resolution”) approving the previously announced plan of arrangement (the “Arrangement”) involving the Company, ClinActiv Holdings Inc. and its wholly-owned subsidiary (the “Purchaser”), pursuant to which the Purchaser will acquire all of the issued and outstanding common shares of the Company (the “Shares”) in exchange for all-cash consideration, subject to the terms and conditions of the arrangement agreement dated March 14, 2026 (the “Arrangement Agreement”). The final order of the Ontario Superior Court of Justice (Commercial List) approving the Arrangement will be sought on May 20, 2026. Completion of the Arrangement remains subject to receipt of the final order, the Company having the minimum cash and net working capital balances at closing, as well as other customary closing conditions. As of May 14, 2026, the Company anticipates that the Arrangement will be completed in the second quarter of 2026. Upon closing of the Arrangement, it is expected that the Shares will be delisted from the Toronto Stock Exchange and that the Company will apply to the applicable Canadian securities regulators to cease to be a reporting issuer under applicable Canadian securities laws. 공시 • Mar 16
ClinActiv Holdings Inc. entered into a definitive arrangement agreement to acquire Crescita Therapeutics Inc. (TSX:CTX) for CAD 15.4 million. ClinActiv Holdings Inc. entered into a definitive arrangement agreement to acquire Crescita Therapeutics Inc. (TSX:CTX) for CAD 15.4 million on March 16, 2026. A cash consideration of CAD 15.4 million valued at CAD 0.8 per share will be paid by the buyer, subject to upward or downward adjustment based on the Company’s net working capital balance at the closing of the Arrangement, subject to a minimum purchase price of CAD 0.75 per Share. As part of consideration, CAD 15.4 million is paid towards common equity of Crescita Therapeutics Inc. The Arrangement Agreement includes a termination fee of CAD 2.0 million, and reverse termination fee of CAD 2.1 million ($1.5 million).
The deal is subject to approval by shareholders of Crescita Therapeutics Inc. and receipt of court approval, and other customary conditions. The Arrangement is conditional on the Company having minimum cash and net working capital balances at closing. The Board of Crescita Therapeutics Inc unanimously recommended that shareholders vote FOR the Arrangement. The deal is is expected to close in the second quarter of 2026.
Bloom Burton Securities Inc. acted as financial advisor and fairness opinion provider for Crescita Therapeutics Inc. Goodmans LLP acted as legal advisor for Crescita Therapeutics Inc. BCF LLP acted as legal advisor for Crescita Therapeutics Inc. Bennett Jones LLP is acting as legal advisor to ClinActiv Holdings. 공시 • Mar 17
Crescita Therapeutics Inc., Annual General Meeting, Jun 04, 2025 Crescita Therapeutics Inc., Annual General Meeting, Jun 04, 2025. 공시 • Jun 27
Crescita Therapeutics Inc. (TSX:CTX) completed the acquisition of Assets of Occy Laboratory for CAD 0.9 million. Crescita Therapeutics Inc. (TSX:CTX) agreed to acquire Assets of Occy Laboratory on June 20, 2024.The transaction was approved by the bankruptcy court, is subject only to customary closing conditions, and is expected to close thereafter.
Crescita Therapeutics Inc. (TSX:CTX) completed the acquisition of Assets of Occy Laboratory for CAD 0.9 million on June 26, 2024. 공시 • Mar 15
Crescita Therapeutics Inc., Annual General Meeting, Jun 05, 2024 Crescita Therapeutics Inc., Annual General Meeting, Jun 05, 2024. 
